TGTX Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . TG Therapeutics
TGTX Stock  USD 42.47  2.59  6.49%   
TG Therapeutics financial statements provide useful quarterly and yearly information to potential TG Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on TG Therapeutics financial statements helps investors assess TG Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting TG Therapeutics' valuation are summarized below:
Gross Profit
290.5 M
Profit Margin
0.0711
Market Capitalization
6.3 B
Enterprise Value Revenue
18.8651
Revenue
329 M
We have found one hundred twenty available fundamental measures for TG Therapeutics, which can be analyzed and compared to other ratios and to its peers in the sector. All investors should make sure to double-check all of TG Therapeutics latest market performance against the performance between 2010 and 2025 to make sure the company can sustain itself this quarter and beyond. Market Cap is likely to rise to about 4.6 B in 2025. Enterprise Value is likely to rise to about 4.7 B in 2025

TG Therapeutics Total Revenue

345.45 Million

Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 195.5 K, Interest Expense of 25.2 M or Total Revenue of 345.5 M, as well as many indicators such as Price To Sales Ratio of 12.63, Dividend Yield of 4.0E-4 or PTB Ratio of 20.65. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
  
Check out the analysis of TG Therapeutics Correlation against competitors.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

TG Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets606.6 M577.7 M212.5 M
Slightly volatile
Other Current Liabilities82 M78.1 M17.7 M
Slightly volatile
Total Current Liabilities95.2 M90.7 M40 M
Slightly volatile
Property Plant And Equipment Net7.5 M7.2 M4.8 M
Slightly volatile
Cash188.9 M179.9 M114.5 M
Slightly volatile
Non Current Assets Total7.6 M11.3 M11.8 M
Slightly volatile
Cash And Short Term Investments326.6 M311 M161.2 M
Slightly volatile
Common Stock Shares Outstanding168.4 M160.3 M78.5 M
Slightly volatile
Total Liabilities373.1 M355.3 M117.4 M
Slightly volatile
Property Plant And Equipment Gross7.5 M7.2 M4.8 M
Slightly volatile
Total Current Assets594.7 M566.4 M200.5 M
Slightly volatile
Other Current Assets16.5 M15.7 M4.5 M
Slightly volatile
Common Stock Total Equity74.7 K131.4 K128.1 K
Slightly volatile
Common Stock107.8 K156 K132 K
Pretty Stable
Short and Long Term Debt Total266.4 M253.7 M55.4 M
Slightly volatile
Other Liabilities260.8 K274.5 K2.4 M
Very volatile
Short Term Debt1.1 M1.2 M2.5 M
Pretty Stable
Current Deferred Revenue12 M11.4 M4.6 M
Pretty Stable
Intangible Assets684 K720 K2.3 M
Slightly volatile
Net Tangible Assets118.5 M66.5 M96.6 M
Slightly volatile
Good Will865.8 K918.9 K789.7 K
Slightly volatile
Long Term Debt Total85.9 M81.8 M35.6 M
Slightly volatile
Capital Surpluse1.9 B1.8 B783.3 M
Slightly volatile
Short and Long Term Debt1.1 M1.1 M1.8 M
Pretty Stable
Net Invested Capital257.1 M466.8 M162.3 M
Slightly volatile
Net Working Capital249.6 M475.7 M157.6 M
Slightly volatile
Capital Stock146.1 K156 K109.3 K
Slightly volatile
Non Current Liabilities Other9.5 M9.3 M14.7 M
Slightly volatile
Capital Lease Obligations8.9 M9.3 M11.4 M
Slightly volatile

TG Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization195.5 K280 K265.2 K
Slightly volatile
Other Operating Expenses301.4 M287.1 M145.9 M
Slightly volatile
Research Development47.7 M94.3 M78.5 M
Slightly volatile
Total Operating Expenses261 M248.6 M140 M
Slightly volatile
Selling General Administrative162 M154.3 M88.5 M
Pretty Stable
Selling And Marketing Expenses11.5 M12.1 M77.4 M
Slightly volatile
Non Operating Income Net Other1.1 M2.1 M1.6 M
Very volatile
Interest Income6.4 M6.1 M2.6 M
Slightly volatile
Reconciled Depreciation319.9 K280 K201.4 K
Slightly volatile

TG Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow57.7 M94.2 M95.7 M
Slightly volatile
End Period Cash Flow190.3 M181.2 M115.1 M
Slightly volatile
Stock Based Compensation44.7 M42.5 M23.8 M
Slightly volatile
Change To Netincome23 M21.9 M19.7 M
Slightly volatile
Issuance Of Capital Stock39.6 M41.7 M128.3 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.6313.29484.2 K
Very volatile
Dividend Yield4.0E-44.0E-46.0E-4
Slightly volatile
Days Sales Outstanding116143137
Very volatile
Book Value Per Share1.451.5302635
Slightly volatile
Average Payables6.3 M6 M5.1 M
Slightly volatile
Stock Based Compensation To Revenue0.120.1293105
Slightly volatile
Capex To Depreciation0.02320.02452.2188
Slightly volatile
Payables Turnover0.40.420.1781
Pretty Stable
Sales General And Administrative To Revenue0.450.469158
Slightly volatile
Average Inventory3.3 M6.1 M4.8 M
Slightly volatile
Research And Ddevelopement To Revenue0.270.2866429
Slightly volatile
Capex To Revenue0.00430.00450.4252
Very volatile
Cash Per Share2.032.1401696
Slightly volatile
Days Payables Outstanding85089461.9 K
Slightly volatile
Intangibles To Total Assets0.00260.00280.0632
Slightly volatile
Net Debt To EBITDA1.341.47941.1347
Slightly volatile
Current Ratio5.796.24586.0645
Slightly volatile
Receivables Turnover2.422.54683.7815
Slightly volatile
Graham Number1.542.35371.562
Slightly volatile
Capex Per Share1.0E-41.0E-430.1944
Slightly volatile
Average Receivables127.6 K155.2 K121.9 K
Pretty Stable
Revenue Per Share2.152.26430.5781
Slightly volatile
Interest Debt Per Share1.821.911311.8568
Slightly volatile
Debt To Assets0.780.43920.3859
Pretty Stable
Days Of Payables Outstanding85089461.9 K
Slightly volatile
Ebt Per Ebit1.060.61040.9484
Slightly volatile
Quick Ratio5.725.02765.9587
Slightly volatile
Net Income Per E B T1.020.91360.9948
Pretty Stable
Cash Ratio1.881.98394.2508
Slightly volatile
Days Of Sales Outstanding116143137
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.0193
Slightly volatile
Fixed Asset Turnover48.3146.008112.1565
Slightly volatile
Debt Ratio0.780.43920.3859
Pretty Stable
Price Sales Ratio12.6313.29484.2 K
Very volatile
Asset Turnover0.410.56950.1111
Slightly volatile

TG Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.6 B4.4 B1.5 B
Slightly volatile

TGTX Fundamental Market Drivers

Forward Price Earnings28.6533
Cash And Short Term Investments311 M

TGTX Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue11.4 M12 M
Total Revenue329 M345.5 M
Cost Of Revenue38.5 M23.1 M
Stock Based Compensation To Revenue 0.13  0.12 
Sales General And Administrative To Revenue 0.47  0.45 
Research And Ddevelopement To Revenue 0.29  0.27 
Revenue Per Share 2.26  2.15 
Ebit Per Revenue 0.13  0.13 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY